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ABSTRACT. The caroteroid compound, crocetin, has been shown to lower plasma lipid
levels in previous animal studies. In this investigation the total cholesterol, HDL
cholesterol and total triglyceride levels were monitored in rats fed two different hyper-
lipemic diets for either 22 or 168 d depending on the diet. Injections of crocetin via
subcutaneous and intraperitoneal routes were compared. No significant hypolipemic
action was observed for any of the groups receiving crocetin injections in this study. The
results clearly show that subcutaneous injections of crocetin in rats do not lower plasma
lipid levels. Since crocetin has been shown to lower plasma lipid levels in rats given
intraperitoneal injections of crocetin, hepatic activation or higher blood concentrations
of the drug is apparently required in rats. The results also suggest that the mechanism
responsible for crocetin's physiological activity is different in rats and rabbits.
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INTRODUCTION
Crocetin (8,8'-diapo-t/>,(//-carotene-
dioic acid) has been used in the treatment
of experimental atherosclerosis in rabbits
and rats (Gainer and Chisolm 1974, Gainer
and Jones 1975, Pool et al. 1976). These
studies along with other investigations
(Gainer et al. 1976, Wilkins et al. 1977,
Chisolm et al. 1973, Wilkins and Gainer
1979) were based on the drug's ability to
increase oxygen diffusivity in plasma
(Chisolm et al. 1972, Chisolm and Gainer
1973). More recently, pharmacokinetic pa-
rameters (J. L. Gainer, pers. comm. 1983)
have been determined.
The physiological mechanism of cro-
cetin activity is not understood, but there
is evidence that it might involve the pre-
vention of hypoxia (Chilsolm et al. 1972,
1973, Gainer and Chisolm 1974, Pool
et al. 1976). The striking reduction in the
severity of experimental atherosclerosis in
rabbits stimulates us to investigate the
mechanism of crocetin activity. Results
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of absorption and fluorescence studies
indicate that crocetin binds strongly to
albumin (Miller et al. 1982). Thus, the
mechanism by which crocetin reduces the
effects of experimental atherosclerosis and
increases oxygen diffusivity must reflect
strong plasma albumin binding.
The initial goal of this study was to
determine if using crocetin in rats with
diet-induced hyperlipemia caused a change
in the relative distribution of plasma lipo-
proteins. The results for several groups of
rats fed two different hyperlipemic diets
are outlined.
METHODS AND MATERIALS
Sprague-Dawley rats weighing about 200 g each
were used. Only male rats were studied, and they
were allowed to eat and drink ad libitum. All
groups were fed either a hypercholesterolemic
(Schurr et al. 1976) or high butterfat (Pool et al.
1976) diet. Different groups of rats were used in
each study.
The crocetin used in this investigation was ex-
tracted from saffron, a spice containing several
carotenoids, in the laboratory of John L. Gainer,
University of Virginia. The purity of samples is
routinely determined spectroscopically (Amax =
420 nm) and by melting point determinations.
The purity was confirmed by HPLC studies in our
laboratory.
Solid crocetin was dissolved in a solution of
0.16 M NaCl that was slightly basic, pH 7.7. One
group of animals was given the drug in 0.01 M
phosphate buffer at pH 7.7, with 0.16 M NaCl.
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Concentrations of crocetin solutions used in the in-
jection program were determined spectroscopically
in terms of SM units. One SM unit is the amount of
crocetin per ml of solution which results in an ab-
sorbance of 1.00 at 445 nm (J. L. Gainer, pers.
comm. 1983). Each crocetin treated group received
subcutaneous or intraperitoneal injections twice a
day, 0.15 units per ml total blood volume. Dosage
was determined by estimating the total blood vol-
ume from body weight. The control animals re-
ceived injections of isotonic saline in comparable
volumes on the same schedule as the treated groups.
Blood samples were taken with heparinized capil-
lary tubes from the medial orbital of the eye with the
animals lightly etherized during the procedure. The
animals were fasted for 16 h before the blood was
collected. Serum samples were stored at 0 to 5°C,
and all analyses were completed within 28 h. Dupli-
cate serum samples were analyzed for all rats, and
the average value is reported for each group.
Total serum cholesterol and triglyceride levels
were determined by the enzymatic method using a
manual procedure (A-Gent reagents by Abbott
Laboratories). The high density lipoprotein (HDL)
cholesterol levels were determined by a precipitation
procedure coupled with the enzymatic method.
Lower density lipoproteins were removed from
the serum by precipitation with a sulfated poly-
sacharride-divalent metal cation reagent (Steel et al.
1976, Warnick and Albers 1978). Pooled serum
standards (Sigma Chemical Co.) were analyzed to
evaluate the reproducibility of the manual enzymatic
methods. The overall relative standard deviation for
all of the results was about seven percent.
RESULTS AND DISCUSSION
Crocetin exhibits unusual chemistry
when dissolved in phosphate buffer (Miller
et al. 1982). Consequently, the first study
was designed to evaluate the effect of cro-
cetin treatment when the drug is adminis-
tered in phosphate buffer. Three groups of
six animals were used in this study: a con-
trol group, a group treated with crocetin in
NaCl solution and a group treated with
crocetin in NaCl solution buffered with
phosphate. All of the animals were fed a
hypercholesterolemic diet (Schurr et al.
1976), and the injection program was ini-
tiated on the day the special diet was intro-
duced. All injections were administered
subcutaneously.
The results of the serum analyses for the
three groups of rats are compiled in
table 1. Over the 168 d of the investiga-
tion no significant difference in the total
cholesterol levels was observed. In fact, the
values for the treated groups were slightly
higher than the control group over most
of the test period. The same trend was
observed for the total serum triglyceride
levels. However, the triglyceride levels
were not substantially elevated. HDL cho-
lesterol levels remained essentially con-
stant during the test period indicating that
crocetin doesn't appear to facilitate the
formation of high density lipoproteins.
Although crocetin has been shown to be
effective in lowering lipid levels in rats
(Pool et al. 1976), no reduction was ob-
served under the experimental conditions
used in study one. However, two im-
portant parameters were varied in this in-
vestigation. First, the diet contained a
much lower level of cholesterol and fat.
The second difference was the injection
mode; the drug was injected subcuta-
neously in this study but by intraperitoneal
injections in the previous rat study (Pool
et al. 1976). A second study was under-
taken to examine these differences.
The high butterfat diet (Pool et al.
1976) was used in the second study. This
diet contains 5.4% cholesterol and
40% butterfat so the plasma lipid levels
are elevated much more. The animals
quickly become lethargic, dehydrated and
contracted severe diarrhea on this diet.
After seven days on the diet, 24 rats were
divided into three groups, and the crocetin
injections were started. Crocetin in
0.16 M NaCl solution was administered
by either subcutaneous or intraperi-
toneal injections.
The results of the serum analyses for the
second study are shown in table 2. After
29 d on the diet and 22 d of treatment, a
substantial increase in total serum cho-
lesterol levels was observed. The results
for the intraperitoneal group is similar to
the earlier study (Pool et al. 1976, J. L.
Gainer, pers. comm. 1983). They observed
initially higher levels of serum cholesterol
in the treated group but after 24 d of treat-
ment, all of the treated groups had lower
cholesterol levels than the control group.
Although not statistically significant,
the trend of lower values after 22 d of
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TABLE 1
Serum lip id levels for study one.
Day
of Test
1
15
38
59
80
119
168
Group*
Control (6)
Water (6)
Phosphate (6)
Control (6)
Water (6)
Phosphate (6)
Control (6)
Water (6)
Phosphate (6)
Control (6)
Water (6)
Phosphate (4)
Control (6)
Water (6)
Phosphate (4)
Control (6)
Water (6)
Phosphate (4)
Control (6)
Water (6)
Phosphate (4)
Total
Cholesterol
(mg/dL)
120 ± 8
118 ± 17
113 ± 10
239 ± 79
223 ± 57
266 ± 39
343 ± 86
409 ± 91
509 ± 129
476 ± 113
457 ± 125
518 ± 99
384 ± 53
403 ± 134
390 ± 123
337 ± 78
411 ± 180
503 ± 59
372 ± 113
449 ± 178
440 ± 98
HDL
Cholesterol
(mg/dL)
37 ± 6
38 ± 6
40 ± 8
32 ± 8
36 ± 5
30 ± 6
45 ± 8
35 ± 5
29 ± 5
38 ± 8
38 ± 11
39 ± 5
34 ± 9
33 ± 8
27 ± 7
37 ± 7
38 ± 10
39 ± 11
55 ± 8
54 ± 3
34 ± 18
Total
Triglycerides
(mg/dL)
124 ± 16
149 ± 17
121 ± 20
101 ± 8
117 ± 20
120 ± 17
138 ± 27
124 ± 21
107 ± 25
113 ± 10
112 ± 9
122 ± 18
106 ± 10
127 ± 30
125 ± 18
129 ± 27
112 ± 15
140 ± 38
141 ± 40
168 ± 64
149 ± 29
"Groups: Control — control group receiving injections of saline. Water — treated group receiving injections
of crocetin in 0.16 M NaCl solution. Phosphate — treated group receiving injections of crocetin in
NaCl solution buffered with phosphate. The number of animals in the group on a given analysis day
is shown in parentheses.
treatment with intraperitoneal injections
began to emerge in our data, but mortality
among this group was high making
interpretation difficult. However, the
cholesterol level for the group receiving
subcutaneous injections was higher than
the control group. There were no sig-
nificant differences among the groups for
either the total triglyceride or HDL cho-
lesterol levels.
Finally, a third study was performed to
clearly establish the trends of serum lipid
levels in animals receiving subcutaneous
injections of crocetin. The conditions out-
lined for study two were employed, but the
drug was only injected subcutaneously.
The results of the serum analyses for the
third study are presented in table 2. It now
appears clear that crocetin administered by
subcutaneous injections is ineffective in
producing the lipid lowering effects ob-
served with intraperitoneal injections.
There are at least two possible explana-
tions for this effect: (1) intraperitoneal in-
jection provides a bolus of material that is
absorbed fairly efficiently and results in
higher crocetin concentrations in the
blood, or (2) microsomal activity of the
liver may be responsible for the lipid low-
ering capacity of crocetin in rats. However,
the mechanism for the effect of crocetin on
lipid levels in rabbits (Gainer and Chisolm
1974, Gainer and Jones 1975, Pool et al.
1976) must be different or the drug must
be effective at much lower levels because
the drug was introduced by intramuscular
injections in those studies. Although cro-
cetin appears to aid in the prevention of
atherosclerosis in rabbits and to reduce the
serum lipid levels in rats, additional in-
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TABLE 2
Serum lipid levels for study two and three.
Study
Two
Three
Day
of Treatment*
0
9
14
22
0
7
14
21
Group**
Control (8)
Subcu (8)
IP (8)
Control (8)
Subcu (7)
IP (6)
Control (7)
Subcu (6)
IP (6)
Control (7)
Subcu (6)
IP (4)
Control (8)
Subcu (8)
Control (8)
Subcu (8)
Control (8)
Subcu (8)
Control (8)
Subcu (8)
Total
Cholesterol
(mg/dL)
227 ± 72
229 ± 48
226 ± 57
540 ± 83
518 ± 91
411 ± 134
431 ± 103
480 ± 120
552 ± 78
574 ± 90
699 ± 114
543 ± 102
228 ± 55
227 ± 54
525 ± 251
427 ± 117
573 ± 196
496 ±212
543 ± 150
684 ± 322
HDL
Cholesterol
(mg/dL)
38 ± 7
37 ± 8
45 ± 14
47 ± 22
56 ± 16
61 ± 26
40 ± 6
27 ± 4
31 ± 4
34 ± 2
33 ± 6
31 ± 6
NA*
NA
NA
NA
NA
NA
NA
NA
Total
Triglycerides
(mg/dL)
193 ± 59
183 ± 37
171 ± 51
308 ± 89
289 ± 48
289 ± 52
356 ± 108
333 ± 54
383 ± 43
242 ± 114
291 ± 120
297 ± 112
167 ± 55
222 ± 79
219 ± 38
241 ± 57
177 ± 41
188 ± 67
245 ± 41
241 ± 76
*Treatment started after seven days on the high butterfat diet.
**Groups: Control — control group receiving injections of saline, subcutaneous once a day and intra-
peritoneal once a day. Subcu — treated group receiving subcutaneous injections of crocetin.
IP — treated group receiving intraperitoneal injections of crocetin. The number of animals in the group
on a given analysis day is shown in parentheses.
*NA— No analysis.
vestigations are required to elucidate the
mechanism responsible for its activity.
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